Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn:
“It was a privilege and pleasure to participate in the British Uro-Oncology Group (BUG) 2026 meeting in Brighton, discussing key updates and perspectives in the adjuvant treatment of renal cell carcinoma (RCC).
A sincere thank you to Amit Bahl for the kind invitation and the opportunity to contribute to such an outstanding conference, as well as to enjoy a remarkably sunny and warm Brighton, made even better by a great run along the coast with my friend and colleague Benjamin Smalley.
I had the honor of contributing to a fantastic session skillfully chaired by Rhona McMenemin alongside my esteemed co-speakers: Sarah Rudman, who delivered an insightful talk on managing non-clear cell RCC and Vincent Khoo, who covered the evolving indications for SBRT in renal cancer.
In my presentation, I focused on key clinical priorities when discussing adjuvant therapy with our patients:
- Communication of risk and benefit: Moving beyond relative measures to discuss individual risk profiles and expected absolute benefits in both disease-free survival and overall survival.
- Overtreatment and toxicity considerations: Balancing treatment escalation with immune-related adverse events (short- and long-term), as well as the burden of long-term steroid use.
- Refining prognostic models: Recognising improved risk-stratification tools like the Leibovich score as important steps forward.
- Multi-party, platform-based collaborative clinical trials: Building robust frameworks for de-escalation and escalation strategies in the adjuvant by incorporating molecular profiling, ctDNA, and emerging biomarkers like KIM-1 to refine patient selection.
This precision-driven approach forms the foundation of our DRIVE-RCC project, which we are proud to lead from Brighton across the UK network.
Thank you again to the organisers, chairs, co-panelists, and all delegates for an engaging exchange of ideas.”
You can also read:
10 Ongoing Clinical Trials on Immunotherapy in Renal Cancer
